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The incidence of carcinoma of the exocrine pancreas has increased
over the last decades, and it is now the fourth leading cause of
cancer death worldwide (Parker et al, 1996). Despite certain
advances in diagnosis, surgical procedures and chemotherapy, the
prognosis of pancreatic cancer remains poor. Resection of the
tumour at an early stage of the disease is the only curative treat-
ment option. Unfortunately, as pancreatic cancer lacks early
symptoms, less than 25% of patients undergo complete resection.
The 5-year survival of these patients has been reported to be less
than 5%, and most of them experience local failure that often
produces debilitating complications, such as pain, jaundice,
duodenal obstruction, malnutrition and haemorrhage (Tepper et al,
1976; Griffin et al, 1990; Warshaw et al, 1992; Gudjonsson et al,
1995).
Therefore, more effective treatment modalities are needed to
increase the number of resectable tumours and to reduce local
failure. In 1987, the Gastrointestinal Tumor Study Group (GITSG)
demonstrated that post-operative chemotherapy combined with
external-beam radiation results in superior survival of patients
with pancreatic cancer after curative resection compared to
surgery alone (Gastrointestinal Tumor Study Group, 1987). The
magnitude of the operation and its associated morbidity, however,
often results in a lengthy period of recovery, which represents a
major obstacle to the routine use of post-operative chemoradiation
(Yeo et al, 1995; Spitz et al, 1997). Accordingly, several more
recent trials have been conducted to investigate the impact of
preoperative chemoradiation. The rationale for the addition of
chemotherapy to irradiation is that cytostatic drugs are able to
enhance the effect of radiation therapy. Combined treatment
modality, when given preoperatively, can also shrink tumour size
and a greater proportion of patients with locally advanced disease
may undergo curative resection.
Despite the availability of more than 50 active chemothera-
peutic agents, only few single agents or combinations of cytotoxic
drugs have demonstrated activity against this tumour (Schnall
et al, 1996).
5-Fluorouracil (5-FU) is the most commonly used single agent
with a median response rate of less than 20%. Inhibition of
thymidilate synthase, the target enzyme of FU, can be enhanced by
leucovorin (LV) because this drug increases the cytosolic levels of
reduced folates (Spitz et al, 1997). Various in vitro investigations
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progression during treatment. The median progression-free interval of the entire study population was 10 months (range 3–32), and median
overall survival was 14.0 months (range 3–45+ months); 53% of all patients were alive at 12 months, and 18% of patients were alive at
24 months respectively. Severe haematological side-effects comprised neutropenia in 18%, thrombocytopenia in 8% and anaemia in 11%.
The most frequent non-haematological side-effects were nausea/vomiting (WHO grade 3: 18%), and diarrhoea (grade 3: 13%). This
combined radiochemotherapy regimen was tolerable and effective in patients with locally advanced pancreatic cancer. Since therapeutic
results, in fact, compare favourably with other series, including surgical treatment of potentially resectable tumours, further evaluation of
combined treatment modalities in the neoadjuvant setting seems warranted. ©2000 Cancer Research Campaign
Keywords :pancreatic cancer; neoadjuvant; chemoradiation; cisplatin; 5-fluorouracil, leucovorin
98
British Journal of Cance r(2000) 82(1), 98–103
©2000 Cancer Research Campaign
Article no. bjoc.1999.0884
Received 25 January 1999
Revised 26 June 1999
Accepted 8 July 1999
Correspondence to : GV KornekTherapy of locally advanced pancreatic cancer with chemoradiation 99
British Journal of Cancer (2000) 82(1), 98–103 © 2000 Cancer Research Campaign
and clinical trials showed that cisplatin (CDDP) consists of a
non-cross-resistant, non-overlapping toxic activity, and exerts a
different and/or further synergistic mechanism of action as
fluorouracil. 5-FU, LV plus cisplatin is a drug combination with
established anticancer activity in head-and-neck, oesophageal and
anal carcinoma (Schnall et al, 1996). The limited therapeutic value
of available chemotherapeutic drug combinations in pancreatic
malignancies and the documented synergistic activity of
5-FU/LV/CDDP, which might be further enhanced by simulta-
neous radiation therapy, prompted us to initiate the present phase
II trial. The goal of our study was to evaluate response rate, overall
survival and tolerance of chemoradiation with this regimen in
previously untreated patients suffering from locally advanced
pancreatic cancer.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically or cytologically confirmed unre-
sectable stage III and IVA adenocarcinoma of the pancreas were
enroled onto this trial between January 1994 and October 1996.
They were required to have a World Health Organization (WHO)
performance status of 0–2, age between 18 and 75 years, life
expectancy of at least 3 months, and adequate bone marrow (WBC
count  ³ 4000 ml–1, platelet count ³ 100 000 ml–1), renal (serum
creatinine concentration < 1.5 mg dl–1) and hepatic functions
(serum bilirubin < 1.5 mg dl–1, serum transaminase level < 2 ´ of
the upper normal range). Patients were staged by laparotomy and
open biopsy, or by fine-needle aspiration cytology following
computerized tomographic (CT) scanning and angiography as
needed to document unresectable disease. Endoscopic ultra-
sonography was also used in the more recent cases. Staging
followed the American Joint Committee (AJCC) tumour-
node-metastasis system (Fleming et al, 1997). All patients had to
have measurable disease that could be assessed by radiographic
procedures. Patients were excluded if they had distant metastases,
serious or uncontrolled concurrent medical illness, known
peripheral polyneuropathy or a history of other malignancies. No
prior chemotherapy or radiation therapy was allowed. Informed
consent was obtained from all patients according to institutional
regulations, and the study was approved by the local ethics
committee.
Pretreatment evaluation included a complete medical history,
physical examination, complete blood cell count, differential
blood cell count, biochemistry analysis, chest X-ray, electro-
cardiogram (ECG) and CT of the abdomen.
Treatment protocol
Chemotherapy
Systemic chemotherapy consisted of LV 20 mg m–2, 5-FU
400 mg m–2, both given as intravenous bolus injection, and
cisplatin 20 mg m–2 given as 90-min infusion. All drugs were
administered on 4 consecutive days, and treatment courses were
repeated every 4 weeks. Sufficient hydration to ensure a urinary
output of at least 100 ml h–1 before and 4 h after the infusion of
cisplatin was required. The administration of mannitol or loop
diuretics was left to the discretion of the investigator. Concomitant
medications routinely given before cytotoxic drug administration
included 8 mg ondansetron and 8 mg dexamethasone. The dose of
all chemotherapeutic drugs was reduced by 25% during concurrent
radiotherapy (second and third course), and if a patient experi-
enced WHO grade 3 organ and/or grade 4 haematological toxicity
during the previous cycle. Elevations of the serum creatinine level
to ³ 150% of the pretreatment value resulted in discontinuation of
cisplatin for one course of the therapy, with resumption only after
return of the serum creatinine to its baseline value. If nephrotoxi-
city persisted at the start of the next cycle of therapy, cisplatin was
withheld. Patients continued to receive their assigned treatment for
a total of six courses, provided that they did not develop pro-
gressive disease.
Radiation therapy
During the second and third chemotherapy cycle, radiotherapy
was delivered using megavolt irradiation of ³ 6 MV photons, most
commonly 10 MV photons, with a three- or four-field technique.
The daily fraction of radiation was 1.8 Gy given 5 days a week to
a prescribed total dose of 55 Gy. Treatment volumes encompassed
the primary tumour, as defined on CT-scans or by clips placed at
the time of surgery, and the areas of potential nodal involvement
with at least a 3 cm margin in all directions covering the pancreati-
coduodenal, porta hepatic and celiac axis lymph nodes for the
initial 45 Gy, followed by a conedown field to the gross tumour
with a margin of 2 cm. Computer-assisted simulation programmes
were used routinely. Treatment was individualized based on the
volume and location of disease. To counteract or avoid nephro-
toxicity and haematological complications, the radiation field was
required to spare the left kidney, and half of the right kidney and
the spinal cord dose was limited to 4000 Gy or less.
Surgical resection of the tumour was not part of the original
protocol; however, it was to be considered 4–6 weeks after comple-
tation of combined radiochemotherapy in responding patients,
provided that they did not initially present with involvement of
major vessels and that they met all clinical and radiological criteria
for resectability as assessed by a CT and angiography reevaluation.
Toxicity and response criteria
Toxicity was evaluated according to WHO standard criteria.
Haematological parameters were assessed every 2 weeks, and all
other adverse reactions were evaluated retrospectively before the
next cycle. For response evaluation, CT reassessments were
repeated every 8 weeks Objective response had to be confirmed in
one subsequent examination after a 4-week interval. A complete
response (CR) was defined as a total resolution of all evidence of
tumour without appearance of new lesions on two consecutive
evaluations 4 weeks apart. A partial response (PR) required a 50%
reduction in the maximum perpendicular tumour measurements,
with no new lesion appearing for at least 4 weeks. No change (NC)
was defined as less than 50% reduction and less than 25% increase
of measurable tumour lesions lasting for at least 8 weeks. Patients
were considered to have progressive disease (PD) if the measur-
able tumour lesions increased by greater than 25% according to
initial staging or if new lesions appeared within the first 2 months
of therapy. For patients who underwent resection after treatment,
the pathologic residual tumour was correlated with the pretreat-
ment tumour mass. Survival was determined from the date of first
treatment until death or until the patient was last examined alive.
Time to progression was determined as the interval between the
date of first treatment and the date PD was first observed.100 GV Kornek et al
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Statistical analysis
Survival and progression-free survival were calculated by the
Kaplan–Meier product method (Kaplan and Meier, 1958).
Survival curves for prognostic factors were compared by the log-
rank test for censored observations (BMDP Statistical Software,
1985). Confidence intervals were calculated at the 95% confidence
level. All patients’ records were examined by independent
reviewers, and all patients who entered the study were analysed.
RESULTS
Patient characteristics
Between October 1994 and July 1996 a total of 38 patients with
locally advanced pancreatic cancer were entered onto this trial.
Their pretreatment characteristics are listed in Table 1. Twenty-
two patients were female and 16 were male, their median age was
60 years, and the median WHO performance status was 1. Twenty-
five patients had carcinomas located in the head of the pancreas,
seven had them in the head and extending into the body of the
pancreas, four patients had primary body tumours, and two
tumours were located in the tail of the pancreas. The size of the
primary tumours ranged from 2 cm to 9 cm with a median of 4 cm.
Previous surgery included palliative digestive and/or biliary anas-
tomosis in 24 patients, and explorative laparatomy in eight. Only
six patients had a fine-needle aspiration biopsy for diagnosis
without laparotomy.
Treatment summary
A total of 181 chemotherapy courses were administered to the 38
patients with a median of five courses per patient (range 2–6).
Cytotoxic drug doses were lowered according to the study protocol
to counteract grade 4 haematotoxicity in four patients (11%), and
severe gastrointestinal side-effects (nausea and vomiting and/or
diarrhoea) in six patients. Twelve patients (32%) had at least one
treatment delay of 1 week some time during therapy, and the total
number of delayed courses was 15. The reasons for delayed
courses were haematological in seven, protracted nausea/vomiting
in three and/or diarrhoea in five cases. In three patients, who
suffered from protracted vomiting and diarrhoea, however, the
underlying reason was found to be tumour progression with infil-
tration of the duodenum and peritoneal carcinomatosis.
Radiotherapy was initiated in all 38 patients, and 34 (89%)
completed the planned treatment course. The median dose of
radiation therapy was 51 Gy (range 12–56 Gy). Four patients did
not complete external-beam radiation; three of them had rapid
tumour progression and one patient was discontinued because of
protracted thrombo- and granulocytopenia. Radiation suspension
occurred in seven patients due to diarrhoea (n = 4) and/or vomiting
(n = 1) and/or haematological toxicity (n = 2).
Table 1 Patient characteristics
No. of patients 38
Age in years
Median 60
Range 30–70
Sex
Female 22
Male 16
WHO performance status
01 8
11 6
24
Clinical stage
III 26
IVA 12
Histological grade
G1 7
G2 16
G3/4 9
GX 6
Location of primary tumour
Head 25
Head and body 7
Body 4
Tail 2
Prior surgery
None 6
Explorative 8
Palliative bypass 24
WHO, World Health Organization.
Table 2 Maximum toxicity in 38 patients treated with combined RCT
Number of patients at toxicity (%)
Type of toxicity 
(WHO grade) 1 2 3 4
Haematological
Leukopenia 17 (45%) 16 (42%) 6 (16%) –
Granulocytopenia 11 (29%) 15 (39%) 4 (11%) 3 (8%)
Thrombocytopenia 9 (24%) 11 (29%) 3 (8%) –
Anaemia 16 (42%) 5 (13%) 3 (8%) 1 (3%)
Non-haematological
Nausea/vomiting 7 (18%) 5 (13%) 7 (18%) –
Stomatitis 4 (11%) 4 (11%) – –
Diarrhoea 3 (8%) 6 (16%) 5 (13%) –
Constipation 3 (8%) – – –
Abdominal pain 3 (8%) 3 (8%) – –
Anorexia 5 (13%) 4 (11%) – –
Alopecia 3 (8%) 1 (3%) 3 (8%) –
Fatigue 4 (11%) 6 (16%) – –
Peripheral neuropathy 3 (8%) – – –
Infection 5 (13%) 3 (8%) – –
Liver 3 (8%) – – –
Kidney 5 (13%) – – –
Table 3 Response to treatment
Variable No. of patients (%)
Complete response 4 (11%)
Partial response 14 (37%)
Stable disease 13 (34%)
Progression 7 (18%)
Overall response rate 18/38 (47%)
95% confidence interval 31–64%
Time to progression, months
Median 10.0
Range 3–35
Survival, months
Median 14.0
Range 3–45+
1-year-survival 20 (53%)
2-year-survival 7 (18%)Therapy of locally advanced pancreatic cancer with chemoradiation 101
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Toxicity
Table 2 summarizes the entire experience of worst-ever toxicities
during all treatment courses with and without concomitant radia-
tion therapy. Haematological toxicity was frequent, but generally
mild to moderate. Only four patients (11%) experienced grade 3
and three patients (7%) grade 4 neutropenia, and there were no
hospitalizations for granulocytopenic fever; the lowest median
absolute granulocyte count was 2630 ml–1 (range 400–
16 600 ml–1). Grade 3 thrombocytopenia occurred in three patients
(7%), and the median platelet count nadir was 148 000 ml–1 (range
42 000–619 000 ml–1). Four patients required red blood cell
transfusion due to symptomatic anaemia, which was grade 3 in
three and grade 4 in one respectively. The most frequently encoun-
tered non-haematological adverse reactions were nausea and
vomiting (49%), which were rated mild to moderate in 12 patients,
and severe in seven. Other common gastrointestinal side-effects
included diarrhoea in 34% (grade 3: five patients), and mild to
moderate mucositis in eight patients (20%). Only three patients
experienced CDDP-related mild and fully reversible peripheral
neuropathy, and temporary renal toxicity occurred in five patients
(13%). Overall, adverse reactions due to irradiation were tolerable
and fully reversible, and included vomiting and diarrhoea, as well
as abdominal pain in six patients.
Therapeutic results and patient outcome
The overall response rate was 47% (95% CI 31–64%), including
four complete (11%) and 14 partial remissions. In 13 patients
(34%) the tumour was rated stable, and in seven patients (18%)
disease progressed. Only 3/18 patients with objective response
underwent surgical exploration (17%). In all of them potentially
curative pancreaticoduodenectomy could be accomplished. One
patient had a histopathologically confirmed complete remission,
and in the two other patients complete resection of the residual
tumour was confirmed at staging of the resected specimens. Of the
responders who did not undergo surgery, the reasons were docu-
mented inoperability due to infiltration/encroachment of the
adjacent large vessels prior to initiation of radiochemotherapy in
eight patients, refusal for surgical exploration in five, or not being
offered surgery because of comorbid medical conditions in
two (pre-existing cardiopulmonary disease and recurrent
thrombophlebitis in one patient each).
The median progression-free interval was 10 months (range
3–38 months), and the median survival duration was 14.0 months
(range 3–45+ months). The overall 1- and 2-year survival rates
were 53% and 18% respectively. The survival of the three patients
who underwent surgical resection following combined
radiochemotherapy was 4, 11 and 12 months. One of these patients
died due to pulmonary embolism, and the two others expired due
to distant metastatic disease recurrence. There was no recogniz-
able impact of prior surgical staging, tumour grade, haema-
tological or biochemical parameters on overall or progression-free
survival.
DISCUSSION
Disappointing results with surgery, chemotherapy and radio-
therapy used individually for stage II and III pancreatic cancer
have stimulated clinical trials of combined modality therapy in
these patients. Many of these studies demonstrated that both radia-
tion and chemotherapy are necessary to achieve best survival
(Nagai et al, 1986; Willet et al, 1993; Gastrointestinal Tumor
Study Group, 1979, 1987, 1988). In view of the reported long-term
results of several contemporary trials, however, further improve-
ments are certainly warranted (Forastiere et al, 1990; Kompki
et al, 1992; Wagener et al, 1992).
The chemotherapeutic drug combination that we have decided
to use in the present trial has been shown to be tolerable and active
against various solid tumours, including pancreatic carcinoma as
indicated in a recent phase II study in patients with metastatic
disease (Hart et al, 1989; Dreyfuss et al, 1990; Vokes et al, 1992;
Scheithauer et al, 1994; Andre et al, 1996). 5-FU is the most
commonly used cytotoxic drug with an objective response rate of
10–20%. Its anti-tumour activity can be enhanced with addition of
radiotherapy as demonstrated in the preclinical and clinical setting
(Byfield et al, 1974; Nakyajima et al, 1979; Moertel et al, 1981).
The concept of biochemical modulation of 5-FU with LV has not
been found successful in patients with metastatic carcinoma of the
pancreas (Bruckner et al, 1988; De Caprio et al, 1989; Crown et al,
1991; Weinermann et al, 1994), however, its potential efficacy
might have been obscured by the bulk of tumour burden in these
patients. Three recently published trials using radiochemotherapy
with 5-FU/LV in locally advanced pancreatic tumours, in fact,
have demonstrated encouraging results with prolonged survival
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Figure 1 Time to progression curve for the entire patient group (n = 38).
The median time to progression was 10.0 months
Figure 2 Survival curve for the entire patient group (n = 38). The median
survival time was 14.0 months, with a 53% 1-year survival rate102 GV Kornek et al
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(Moertel et al, 1994; Mohiuddin et al, 1995; Prott et al, 1997). The
use of cisplatin in the regimen was based on preclinical evidence
that CDDP is a potent radiosensitizer and on its successful addition
to 5-FU ± radiation in the treatment of pancreatic and other malig-
nancies, including squamous cell carcinoma of the head and neck,
oesophageal and anal carcinoma (Rothman et al, 1991; Nicolson et
al, 1995; Hörmann, 1996; Popescu et al, 1997).
The overall response rate of 47% in the present trial, including
four radiological complete responses and one pathological
complete response, demonstrates that this combination of two
potential radiosensitizers with concomitant radiotherapy provides
an active regimen for the treatment of patients with locally
advanced pancreatic carcinoma. The local control of the primary
tumour site was effective and durable: none of the three surgically
explored and curatively resected patients, and only one out of the
remaining 12 responders progressed within the radiation field.
Among patients with stable disease, there were also only two
cases, who failed locally. Similarly, the 1- and 2-year survival rates
(53% and 18%) seem encouraging and at least comparable with
other series, although we were able to achieve these results in a
study population including patients who were likely to have been
excluded from other trials of preoperative radiochemotherapy
because of primarily inoperable disease (Klaasen et al, 1985;
Forastiere et al, 1990; Kompki et al, 1992; Wagener et al, 1992;
Yeung et al, 1993; Moertel et al, 1994; Mohiuddin et al, 1995;
Kamthan et al, 1997; Prott et al, 1997; Hoffman et al, 1998).
The fact that a number of our patients initially presented with
portal vein occlusion or infiltration of mesenterial vessels, and/or
involved regional lymph nodes, also contributed to the low rate of
surgical explorations despite the high objective response rate
obtained with this combined modality therapy. Probably, we have
also underestimated the potential rate of technically feasible resec-
tions, because some additional patients with evidence of residual
tumour on imaging studies rated stable may actually have had
fibrosis or significantly reduced residual tumour volume and were
resectable. Such experience has been reported in neoadjuvant trials
of non-small-cell lung and pancreatic cancers with less advanced
and resectable disease (Gralla, 1988; Yeung et al, 1993; Evans et
al, 1994).
Another important positive feature of this combined
radiochemotherapy regimen with 5-FU/LV/CDDP was its toler-
ance, with 89% of patients completing treatment. Grade 4 myelo-
suppression was seen in 8%, and severe gastrointestinal
side-effects, requiring dose attenuations, occurred in only 13%.
There were no life-threatening toxicities, and no treatment-related
deaths occurred.
Based on our results in patients with initially unresectable,
locally advanced pancreatic adenocarcinoma, this chemoradio-
therapy regimen deserves further evaluation as neoadjuvant
treatment for earlier stages. Despite sophisticated diagnostic tech-
niques, the majority of patients prove to be unresectable, and
exploratory surgery often only delays treatment. As demonstrated
in a recent trial involving 142 patients with localized tumours of
the pancreatic head, preoperative chemoradiation followed by
resection resulted in a similar therapeutic outcome when compared
with primary resection followed by adjuvant chemoradiation
(Spitu et al, 1997). Twenty-six per cent of the patients, who were
found to have disseminated disease after completing preoperative
treatment, however, were spared an unnecessary laparotomy.
Another advantage of the preoperative approach was related to the
fact that all patients received all components of the multimodality
regimen in contrast to adjuvant therapy, which in agreement with
other series, could not be delivered in one fourth of eligible patient
due to prolonged recovery after pancreaticoduodenectomy (Yeo
et al, 1995; Spitz et al, 1997).
Further improvements in combined modality treatment might be
achieved by using rapid-fractionation radiotherapy implicating the
advantage of a much shorter duration of treatment, and by estab-
lishing new drugs and combinations that are more effective in
counteracting systemic tumour spread which, in line with our
experiences, remains responsible for the limited survival duration
in patients with pancreatic cancer (Spitz et al, 1997).
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